In addition, future prospective studies will need to establish whether semaglutide and tirzepatide provide significant cardiorenal benefits without increasing the risk of severe hypoglycemia, DKA and euDKA in patients with autoimmune diabetes who use different methods of insulin delivery (MDI insulin therapy, insulin pumps, AID systems). This evidence concerns the gene INS and Hypoglycemia.